These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 15956013)

  • 1. The (variable) definition of benefit in the case of clopidogrel vs aspirin.
    Hansen DB
    Arch Intern Med; 2005 Jun; 165(11):1310; author reply 1310-1. PubMed ID: 15956013
    [No Abstract]   [Full Text] [Related]  

  • 2. [Myocardial infarct, stroke and vascular events reduced by a third].
    Z Kardiol; 1997 Nov; 86(11 Suppl Myokardinf):1-3. PubMed ID: 9437253
    [No Abstract]   [Full Text] [Related]  

  • 3. Clopidogrel: a novel antiplatelet agent.
    D'Sa S; Machin SJ
    Hosp Med; 1999 May; 60(5):362-3. PubMed ID: 10396413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CAPRIE trial.
    Toplak H; Bahadori B; Wascher TC
    Lancet; 1997 Feb; 349(9048):354; author reply 356. PubMed ID: 9024394
    [No Abstract]   [Full Text] [Related]  

  • 5. Antiplatelet therapy in peripheral arterial disease.
    Aronow WS
    Curr Drug Targets Cardiovasc Haematol Disord; 2004 Sep; 4(3):265-7. PubMed ID: 15379619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease.
    Tran H; Anand SS
    JAMA; 2004 Oct; 292(15):1867-74. PubMed ID: 15494585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone.
    Rothberg M
    Ann Intern Med; 2005 Sep; 143(6):464; author reply 464-5. PubMed ID: 16172448
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone.
    Eriksson P
    Ann Intern Med; 2005 Sep; 143(6):464; author reply 464-5. PubMed ID: 16172447
    [No Abstract]   [Full Text] [Related]  

  • 9. Antiplatelet drugs for patients at high cardiovascular risk. Aspirin generally remains the best choice.
    Prescrire Int; 2009 Dec; 18(104):272-3. PubMed ID: 20027714
    [No Abstract]   [Full Text] [Related]  

  • 10. CAPRIE trial.
    Violi F
    Lancet; 1997 Feb; 349(9048):354; author reply 356. PubMed ID: 9024393
    [No Abstract]   [Full Text] [Related]  

  • 11. The role of platelets in peripheral arterial disease: therapeutic implications.
    Matsagas MI; Geroulakos G; Mikhailidis DP
    Ann Vasc Surg; 2002 Mar; 16(2):246-58. PubMed ID: 11972262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New antiplatelet agents: ticlopidine and clopidogrel. Antiplatelet therapy but at what cost?
    Black C; Paterson KR
    Adverse Drug React Toxicol Rev; 2001 Dec; 20(4):277-303. PubMed ID: 11770173
    [No Abstract]   [Full Text] [Related]  

  • 13. Clopidogrel: new indication. In combination with aspirin: marginal additional benefits.
    Prescrire Int; 2007 Aug; 16(90):146. PubMed ID: 17724837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clopidogrel--a myocardial infarction CURE?
    Bradley C
    Intensive Crit Care Nurs; 2001 Dec; 17(6):364-6. PubMed ID: 11853013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction.
    Chua D; Lo C; Babor EM
    N Engl J Med; 2005 Jun; 352(25):2647-8; author reply 2647-8. PubMed ID: 15972875
    [No Abstract]   [Full Text] [Related]  

  • 16. Antiplatelet therapy and the vascular tree.
    Blann A
    Heart; 2006 Jan; 92(1):3-4. PubMed ID: 16216852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiplatelet therapy: a vascular medicine perspective.
    Olin JW
    Manag Care; 2000 Oct; 9(10 Suppl):9-12. PubMed ID: 11729422
    [No Abstract]   [Full Text] [Related]  

  • 18. Antiplatelet therapy: a vascular medicine perspective.
    Olin JW
    Manag Care; 2000 May; 9(5 Suppl):11-4. PubMed ID: 11729407
    [No Abstract]   [Full Text] [Related]  

  • 19. Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis.
    Schleinitz MD; Weiss JP; Owens DK
    Am J Med; 2004 Jun; 116(12):797-806. PubMed ID: 15178495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial.
    Bhatt DL; Flather MD; Hacke W; Berger PB; Black HR; Boden WE; Cacoub P; Cohen EA; Creager MA; Easton JD; Hamm CW; Hankey GJ; Johnston SC; Mak KH; Mas JL; Montalescot G; Pearson TA; Steg PG; Steinhubl SR; Weber MA; Fabry-Ribaudo L; Hu T; Topol EJ; Fox KA;
    J Am Coll Cardiol; 2007 May; 49(19):1982-8. PubMed ID: 17498584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.